It’s only fair to share… BMS 986158 MF C30H33N5O2, MW495.627 g/mol CAS 1800340-40-2 5H-Pyrido[3,2-b]indole-7-methanol, 3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-α,α-dimethyl-5-[(S)-phenyl(tetrahydro-2H-pyran-4-yl)methyl]- MOA：Bromodomain and extraterminal domain protein inhibitor Indication：Solid tumoursStatus： Phase II ：Bristol-Myers Squibb (Originator) Phase I/IISolid tumours Originator Bristol-Myers Squibb Class Antineoplastics; Small molecules Mechanism of Action Bromodomain and extraterminal domain protein inhibitors 01 Jun 2015 Phase-I/II clinical trials for Solid tumours (Late-stage disease, Metastatic disease) …
GLGP 1837
It’s only fair to share… GLGP 1837 CAS 1654725-02-6 MF C16 H20 N4 O3 S, MW 348.42 For cystic fibrosis treatment N-(3-carbamoyl-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide 1H-Pyrazole-3-carboxamide, N-[3-(aminocarbonyl)-4,7-dihydro-5,5,7,7-tetramethyl-5H-thieno[2,3-c]pyran-2-yl]- Inventors Der Plas Steven Emiel Van, Sébastien Laurent Xavier MARTINA, Sébastien Jean-Jacques Cédric DROPSIT-MONTOVERT, Martin James Inglis Andrews, Hans KELGTERMANS Applicant Galapagos Nv SYNTHESIS GLGP 1837 ABC transporters are a family of …
EVP 4593
It’s only fair to share… EVP4593; EVP 4593; EVP-4593 M.Wt 356.42 545380-34-5; QNZ (EVP4593); QNZ; 6-Amino-4-(4-phenoxyphenylethylamino)quinazoline; N4-(4-phenoxyphenethyl)quinazoline-4,6-diamine; Formula C₂₂H₂₀N₄O CAS No 545380-34-5 QNZ(EVP4593) is a derivative of 6-aminoquinazoline class that has been previously isolated as an inhibitor of PMA/PHA-induced NF-κB pathway activation in Jurkat cells (IC50= 9 nM). QNZ(EVP4593) is a derivative of 6-aminoquinazoline class …
The greening of peptide synthesis
It’s only fair to share… The greening of peptide synthesis Stefan B. Lawrenson,a Roy Arava and Michael North*a *Corresponding authors aGreen Chemistry Centre of Excellence, Department of Chemistry, University of York, York, UK E-mail: Michael.north@york.ac.uk Abstract The synthesis of peptides by amide bond formation between suitably protected amino acids is a fundamental part of …
Process Development and Good Manufacturing Practice Production of a Tyrosinase Inhibitor via Titanium-Mediated Coupling between Unprotected Resorcinols and Ketones
It’s only fair to share… (S)-4-(2,4-Dihydroxyphenyl)-N-(1-phenylethyl)piperidine-1-carboxamide (1) In a………………….. to yield crude 1 (3.51 kg, 77%, 97.7 A% purity). Recrystallization: In a 100 L double jacketed reactor were charged crude 1 (3.51 kg, 10.31 mol, 1.0 equiv), iPrOH (27.0 L, 7.5 vol), AcOH (74.1 g), and water (27.0 L, 7.5 vol). The suspension was warmed …
Enantioselective synthesis of a cyclobutane analogue of Milnacipran
It’s only fair to share… (1R,2S)-2-(Aminomethyl)-N,N-diethyl-1 phenylcyclobutanecarboxamide (19) 1 H NMR (CDCl3) δ 7.36–7.33 (m, 4H), 7.25–7.21 (m, 1H), 3.51–3.43 (qd, J = 13.8 Hz, 6.8 Hz, 1H), 3.15–2.87 (m, 7H), 2.81–2.72 (m, 2H), 2.23–2.14 (m, 1H), 2.04–1.97 (m, 1H), 1.62 (tdd, J = 10.5 Hz, 5.7 Hz, 2.6 Hz, 1H), 1.07 (t, J …
Debio-1452
It’s only fair to share… Debio-1452, AFN 1252 AFN-1252; UNII-T3O718IKKM; API-1252; CAS 620175-39-5; CHEMBL1652621; (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide MFC22 H21 N3 O3 2-Propenamide, N-methyl-N-[(3-methyl-2-benzofuranyl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- MW375.42 Phase 2, clinical trials for the oral treatment of staphylococcal infections, including hospital and community-acquired MRSA and acute bacterial skin and skin structure infections Qualified Infectious Disease Product designation GlaxoSmithKline plc INNOVATOR Debiopharm …
FDA approves new drug to treat multiple sclerosis Ocrevus (ocrelizumab)
It’s only fair to share… FDA approves new drug to treat multiple sclerosis 03/29/2017 On March 28, the U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). This is the first drug approved by the FDA for PPMS. Ocrevus …
QUILSECONAZOLE, VT 1129, New Patent, WO, 2017049080, Viamet
It’s only fair to share… VT 1129 BENZENE SULFONATE CAS 1809323-18-9 VT 1129 1340593-70-5 CAS MF C22 H14 F7 N5 O2, MW 513.37 2-Pyridineethanol, α-(2,4-difluorophenyl)-β,β-difluoro-α-(1H-tetrazol-1-ylmethyl)-5-[4-(trifluoromethoxy)phenyl]-, (αR)- R ISOMER ROTATION + QUILSECONAZOLE, VT-1129 Viamet, in collaboration with Therapeutics for Rare and Neglected diseases, is investigating quilseconazole benzenesulfonate (VT-1129), a small-molecule lanosterol demethylase (CYP51) inhibitor, developed using the company’s …
FDA approves new eczema drug Dupixent (dupilumab)
It’s only fair to share… FDA approves new eczema drug Dupixent 03/28/2017 The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable. Dupixent …